Cookie Preference

This website uses cookies to improve user experience. Please select an option.  Privacy Policy

No cookies except for those necessary for technical reasons are set.


iThera to initiate a pivotal clinical trial with its optoacoustic imaging technology in inflammatory bowel disease (IBD)

Ascenion’s portfolio company iThera gained regulatory approval for a pivotal trial evaluating its MSOT imaging technology for the assessment of colon inflammation. If successful, it could provide a superior, non-invasive alternative to colonoscopy.

iThera’s MSOT technology (multispectral optoacoustic tomography) has the unique capability of visualizing optical contrast at high resolution in deep tissue and displaying the image in real time. It is already in use for preclinical and clinical research around the globe and is currently being developed for diagnostic applications. Results from a pilot study in patients with inflammatory bowel disease suggest that the approach has potential to non-invasively measure disease activity in people with Crohn’s Disease (CD) and Ulcerative Colitis (UC). This could help adapt treatment strategies and prevent persistent inflammation, which is related to higher complication rates, hospitalization and cancer.

The pivotal trial in IBD will involve four investigational sites across Germany and Italy.

Further information: See iThera’s press release